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ABSTRACT 
 
Worldwide, the beta interferons remain the most commonly prescribed disease-modifying drugs 
for multiple sclerosis. However, it is unclear if they alter survival. We investigated the 
association between beta interferon and mortality in the ‘real-world’ setting. This was a multi-
centre population-based observational study of patients with relapsing-onset multiple sclerosis 
who were initially registered at a clinic in British Columbia, Canada (1980-2004) or Rennes, 
France (1976-2013). Data on this cohort were accessed from the clinical multiple sclerosis 
databases and from individually linked health administrative data; all data were collected 
prospectively. Participants were followed from the later of their first multiple sclerosis clinic 
visit, 18
th
 birthday or 1
st
 January 1996; until death, emigration or 31
st
 December 2013. Only 
those who were naïve to disease-modifying therapy and immunosuppressant treatment of 
multiple sclerosis at the start of their follow-up were included in the analysis. A nested case-
control approach was used. Up to 20 controls, matched to cases (deaths) by country, sex, age+/- 
five years, year and disability level at study entry, were randomly selected from the cohort by 
incidence density sampling. The associations between all-cause mortality and at least six months 
beta interferon exposure, and also cumulative exposure (‘low’, six months to three years; and 
‘high’, more than three years), were estimated by conditional logistic regression adjusting for 
treatment with other disease-modifying therapies and age in years. Further analyses included 
separate analyses by sex and country, additional adjustment for comorbidity burden in the 
Canadian cohort, and estimation of the association between beta interferon and multiple 
sclerosis-related death in both countries. 
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Among 5,989 participants (75% women) with a mean age of 42 [SD 11] years at study entry, 
there were 742 deaths (70% women) and the mean age at death was 61 [SD 13] years. Of these 
cases, 649 were matched to between one and 20 controls. Results of the conditional logistic 
regression analyses are expressed as adjusted odds ratios with 95% confidence intervals. The 
odds of beta interferon exposure were 32% lower among cases than controls (0.68; 0.53-0.89). 
Increased survival was associated with more than three years beta interferon exposure (0.44; 
0.30-0.66), but not between six months and three years exposure (1.00; 0.73-1.38). Findings 
were similar within sex and country, and for multiple sclerosis-related death. Beta interferon 
treatment was associated with a lower mortality risk among people with relapsing-onset multiple 
sclerosis. Findings were consistent between two geographically distinct regions in North 
America and Europe. 
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Abbreviations: CI Confidence interval; OR Odds ratio; SD Standard deviation  
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INTRODUCTION 
Multiple sclerosis is a devastating chronic disease of the central nervous system that typically 
first affects young adults. Multiple sclerosis confers a survival disadvantage in comparison to the 
general population, with six to 14 fewer years lived (Bronnum-Hansen et al., 2004; Kingwell et 
al., 2012; Scalfari et al., 2013; Rodriguez-Antiguedad Zarranz et al., 2014; Leray et al., 2015; 
Marrie et al., 2015). Among people with multiple sclerosis, the proportion of deaths directly 
attributed to this condition has ranged from 50% to more than 75% (Sadovnick et al., 1991; 
Midgard et al., 1995; Koch-Henriksen et al., 1998; Leray et al., 2007; Rodriguez-Antiguedad 
Zarranz et al., 2014; Leray et al., 2015). 
The first disease-modifying drugs, the beta interferons, were approved to treat relapsing-onset 
multiple sclerosis in the 1990s. Although newer therapies are now available, including orally 
active and infused medications, the beta interferons remain among the most commonly 
prescribed for multiple sclerosis worldwide (Multiple Sclerosis International Federation; Westad 
et al., 2017). However, while they have shown modest efficacy in short-term clinical trials 
including reductions in relapse rates, relapse severity, and MRI abnormalities (IFNB Multiple 
Sclerosis Study Group, 1993; Johnson et al., 1995; Jacobs et al., 1996; PRISMS (Prevention of 
Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study 
Group, 1998) their effects on disability progression, or over the long-term and in clinical practice 
are less certain (Tramacere et al., 2015; Signori et al., 2016). 
Preliminary observations from a small group of 366 individuals who were enrolled in one of the 
original beta interferon-1b clinical trials suggested that this drug might increase survival and 
reduce the risk of multiple sclerosis-related death (Goodin et al., 2012a; Goodin et al., 2012b). 
However, concerns were raised over the study design, including post hoc analyses in a small 
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group of clinical trial participants; it remains possible that the observed survival advantage was 
due to chance alone (Goodin and Reder, 2012; Gronseth and Ashman, 2012). Long-term 
randomized clinical trials that are specifically designed to assess the survival impact of disease-
modifying therapies are neither feasible nor ethical. We utilized the nested case-control approach 
with a large population-based combined cohort of relapsing-onset multiple sclerosis patients 
from British Columbia, Canada  and Rennes, France to examine the association of the beta 
interferons with all-cause, and multiple sclerosis-related, mortality in the real-world clinical 
setting.  
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MATERIALS AND METHODS 
Data and cohort selection 
We used prospectively collected linked data from population-based multiple sclerosis clinical 
and health administrative databases. The cohort comprised adults with relapsing-onset multiple 
sclerosis, initially registered at one of the four multiple sclerosis clinics in British Columbia 
between 1980 and 2004, or the Rennes multiple sclerosis clinic between 1976 and 2013. These 
individuals were inked to their health administrative data via unique personal health number 
(Canada), or name, sex, birthdate and birthplace (France). This enabled access to provincial 
(Canada) and national (France) death dates, and all causes listed on the death certificate. 
Additional linkage, for Canada only, provided outpatient and community dispensations of 
disease-modifying therapy; hospital and physician derived diagnoses recorded via the 
International Classification of Diseases system to calculate the Charlson Comorbidity Index 
(Deyo et al., 1992); registration dates in the compulsory provincial healthcare plan (to confirm 
residency in British Columbia; and quintiles of estimated socioeconomic status based on 
neighbourhood income. See Supplementary Methods 1 and Supplementary Table 1 for details. 
Only persons with relapsing-onset multiple sclerosis (i.e. relapsing remitting or secondary 
progressive multiple sclerosis at study entry) who were naïve to any disease-modifying therapy 
or immunosuppressant at study entry were included. For the main analyses, an Expanded 
Disability Status Scale score within three years of study entry was required for inclusion. The 
study entry was the most recent of 1
st
 January 1996, the first clinic visit, or the 18
th
 birthday. The 
first full calendar year of beta interferon availability in both jurisdictions was 1996 (prior use 
was limited to clinical trials). Follow-up continued until the earlier of death, 31
st
 December 2013 
or, for the Canadian cohort only, emigration from the province of British Columbia. Such 
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censoring at emigration from British Columbia was necessary because death outcomes and 
treatment exposure were only captured for residents of the province. Treatment status after the 
last clinic visit was unknown for a subset of the French cohort; follow-up for these individuals 
was censored at their last clinic visit. However, all deaths registered anywhere in France were 
captured, and while emigration from France was not captured this was considered negligible. 
Outcome and Exposure Measures  
The primary outcome was death due to any cause; all persons who died during follow-up were 
considered cases. The secondary outcome was multiple sclerosis-related death, identified using 
the underlying or contributing causes on the death certificate by a study-specific algorithm 
formulated a priori (Figure 1). The algorithm was developed by reference to the existing 
literature on increased mortality risk due to specific causes among people with multiple sclerosis 
(Sadovnick et al., 1991; Koch-Henriksen et al., 1998; Bronnum-Hansen et al., 2004; Grytten 
Torkildsen et al., 2008; Smestad et al., 2009; Sumelahti et al., 2010; Goodin et al., 2014), and by 
consensus of the study team which included two experienced multiple sclerosis specialist 
neurologists (GE and JO). For this analysis, multiple sclerosis-related deaths were cases and all 
other deaths in the cohort during follow up were censored on the date of death. 
All beta interferons were considered as one group; ‘exposed’ was defined as six or more months 
of cumulative exposure between study entry and death, or between study entry and the analogous 
date for controls. Lower (six months to three years), or higher (more than three years) cumulative 
exposure to beta interferon was considered in secondary analysis to explore potential dose-
response relationships; exposure duration categories were determined a priori based on the 
distribution of beta interferon exposure in the cases and controls combined. The effects of ‘early’ 
or ‘late’ beta interferon initiation were also examined by (i) time since multiple sclerosis 
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symptom onset (less than five and five or more years); and (ii) age (under 40 years and 40 years 
or older). Exposure to the second most commonly used disease-modifying therapy during this 
study period, glatiramer acetate (for at least six months) was considered as a covariate. The six 
month minimum exposure for beta interferon and glatiramer acetate was decided upon with 
reference to the minimum length of time that these agents might be expected to yield a clinical 
response (Karussis et al., 2006).  All other disease-modifying therapies that were available or 
approved during the study period (immunosuppressants such as azathioprine or mitoxantrone, as 
well as natalizumab and fingolimod) were combined into one variable and categorized as ‘any’ 
(at least one day) or ‘no’ exposure. The one day minimum exposure for the ‘other disease-
modifying therapy’ variable reflects both its heterogeneous nature and the assumption that 
exposure to any duration of these therapies could serve as a marker for more severe disease.  
The sample size required to address the primary and secondary questions of the association 
between beta interferon and all-cause mortality, and MS-related mortality, was estimated a 
priori, assuming a two-tailed test with a 5% probability of type I error and at least 80% power. 
We anticipated sufficient power to assess the effects of beta interferon exposure on all-cause 
death, and MS-related death. Given low exposure rates for the non-beta interferon therapies 
(glatiramer acetate and ‘other’ disease modifying therapies) in this cohort, we did not have 
sufficient power to query their effects on survival; these exposures were measured and included 
in the analyses to adjust for confounding. 
Study Design 
A nested case-control approach was used with incidence density sampling. Up to 20 controls 
were randomly selected for each case, matched at study entry by sex, country, age (+/- five 
years), calendar year, and Expanded Disability Status Scale score (within three years of study 
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entry and categorized as scores of <3.0; 3.5-5.0; 5.5-6.5; >6.5). Hence, controls were alive at the 
time of the case’s death, cases and controls were matched for follow-up duration, and eligible 
controls could be selected for more than one case or could become cases later during follow-up. 
If only 20 or fewer controls were available all available matched controls were used; all cases 
with at least one control were included in the analysis. The odds ratio (OR) estimated with this 
approach will be very similar to the hazard ratio that would be obtained using Cox regression 
modeling (when the parametric assumptions of the Cox model are met) of the whole cohort with 
time dependent disease-modifying therapy exposures (Essebag et al., 2005). However, the nested 
case-control approach provides tighter control of the important confounding variables through 
matching. The cases are directly compared only to persons in the cohort who are still alive at the 
time of the death in the case and who are similar to them in terms of age; sex; disability level; 
and time period and duration of follow-up. As with the time dependent Cox model, the nested 
case-control approach accounts for the time dependence of exposure, and varying levels of 
exposure over time. 
Statistical Analyses 
The ORs and corresponding 95% CIs were estimated using conditional logistic regression 
models adjusted for a more precise measure of age (in years and months) at study entry, 
exposure to glatiramer acetate, and exposure to other disease-modifying therapies. Disease 
duration (years between multiple sclerosis onset and study entry), and in Canada only, the 
quintile of socioeconomic status at study entry and the Charlson Comorbidity Index measured 
over the year before study entry, were included in multivariable models only if associated with 
case-control status in the univariate model (p<0.1). ORs were estimated for the combined cohort, 
and separately by country and sex. 
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Complementary analyses facilitated inclusion of additional data and tested assumptions by: 
allowing earlier study entry (1
st
 January 1986); imputing Expanded Disability Status Scale scores 
for those without a score at study entry; imputing beta interferon status after the last clinic visit if 
subsequent treatment was unknown (France only); and changing criteria for exposure to beta 
interferon or glatiramer acetate to at least one day (‘intention to treat’). More details are provided 
in Supplementary Methods 2. 
The analyses were performed using R (version 3.4.2). The study was approved by the relevant 
ethics boards and data stewards (see acknowledgements). 
Data Availability 
The individual clinical data and linked administrative health and vital statistics data that support 
these findings are protected by strict privacy and data sharing agreements and cannot be 
distributed openly. 
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RESULTS 
The combined Canadian and French cohort included 5,989 persons with relapsing-onset multiple 
sclerosis who were naïve to disease-modifying therapies at study entry; 75% were women and 
the mean age was 42 (SD 11) years. During an average of 11, and up to 18, years of follow-up 
32% of persons in the cohort were exposed to beta interferon for at least six months, 12% to 
glatiramer acetate for at least six months, and 13% to another disease-modifying therapy for at 
least one day. 
There were 742 deaths due to any cause (mean age at death was 61 years [SD 13]). Of these, 649 
were successfully matched with up to 20 controls; the number of controls per case is shown in 
Supplementary Table 2. At study entry, cases were slightly older than controls, although by less 
than half a year (50.7 versus 50.3; p=0.002), and comparable by sex, Expanded Disability Status 
Scale score and country (Table 1). Comorbidity was associated with case-control status (p=0.02) 
in the Canadian cohort whereas multiple sclerosis disease duration and socioeconomic status 
were not (p>0.20).  
After adjustment for age and other disease-modifying therapy exposure, persons with relapsing-
onset multiple sclerosis who died had lower odds of beta interferon exposure compared to 
persons with relapsing-onset multiple sclerosis who survived (OR:0.68; 95% CI:0.53-0.89); this 
can be interpreted as a 32% lower mortality risk for exposed compared to unexposed individuals. 
Increased survival was associated with a higher cumulative beta interferon exposure (more than 
three years; OR:0.44; 95% CI:0.30-0.66) but not with a lower exposure (between six months and 
three years; OR:1.00; 95% CI:0.73-1.38) (Table 2). 
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Stratified analyses by country (Table 2) and sex (Table 3), resulted in qualitatively similar 
findings, although CIs were wider in these subgroups. The adjusted ORs for Canada and France 
were essentially identical but for the smaller French cohort, with 80 matched cases, the CI 
included one (Table 2). While findings did not differ significantly between the sexes (the CIs 
overlapped), statistical significance was not reached for women except with higher cumulative 
beta interferon exposure. Further, the effect size was greater among men than among women 
(Table 3).  
Since the analysis included people who died before the end of follow-up (cases) and their 
matched controls of comparable age, sex and disability level, both the average age (50 years) and 
the average disease duration (17 years) at study entry were greater than the average age and 
disease duration of the source cohort (i.e. those who were older or had a longer disease duration 
at study entry were less likely to survive to study end). The older age and more advanced disease 
duration at study start means that few had the opportunity to start treatment ‘early’ (at less than 
five years disease duration or under age 40); consequently, the proportion of cases and controls 
who initiated beta interferon early was less than 5% (Table 1). Our assessment of the effects of 
delayed initiation, whether measured by time since disease onset or age, resulted in findings 
consistent with the main analyses, with no evidence that late initiation was disadvantageous (the 
CIs for early and late initiation overlapped, and for early initiation they included one; Tables 2 
and 3). 
Among the 742 deaths, 489 (66%) were multiple sclerosis-related with a mean age at death of 59 
years (SD 13); of these 433 were matched with up to 20 controls. As with all-cause deaths, the 
odds of beta interferon exposure were lower among multiple sclerosis-related death cases 
compared to their matched controls (OR:0.71; 95% CI:0.51-0.98). When analysed by cumulative 
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exposure or separately by sex, findings for multiple sclerosis-related death were similar to the 
all-cause death analysis (lower exposure: OR:1.15; 95% CI:0.78-1.68; higher exposure: OR:0.38; 
95% CI:0.23-0.63; women OR:0.84; 95% CI:0.58-1.21; men OR:0.38; 95% CI:0.18-0.80). 
An earlier study entry date (1st January 1986), imputation of missing Expanded Disability Status 
Scale scores, and imputation of treatment status for those with unknown beta interferon exposure 
after their last clinic visit allowed inclusion of more cases (up to 956) and a longer follow-up of 
up to 28 years. All findings from these complementary analyses, including the ‘intention to treat’ 
approach, were consistent with the main analyses although the estimated effect was greater with 
imputation of beta interferon exposure (see Supplementary Methods 2 and Supplementary Tables 
3, 4, 5 and 6). 
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DISCUSSION  
 
We observed a survival advantage associated with beta interferon exposure among persons with 
relapsing-onset multiple sclerosis; those who were exposed to beta interferon had a 32% lower 
mortality risk when compared to those who were not exposed. These findings were consistent 
between two geographically distinct multiple sclerosis cohorts, for men and women, and when 
only multiple sclerosis-related deaths were considered. Further, we found evidence of a 
cumulative dose response, with an increased survival associated with a longer (more than three 
years) but not with shorter (between six months and three years) cumulative exposure to beta 
interferon. 
There are few published studies with which to compare our findings. Observations from a cohort 
of 366 relapsing-remitting multiple sclerosis participants in a beta interferon clinical trial, of 
which 81 died, suggested a survival advantage among those randomized to beta interferon 
compared to placebo 21 years previously (Goodin et al., 2012b). However, there were no 
available data on the baseline distribution of risk factors for shorter survival, such as smoking, 
lipid status or comorbidity, and the analyses of the survival outcomes were post-hoc (Goodin and 
Reder, 2012; Gronseth and Ashman, 2012) A Taiwanese population-based study which included 
88 deaths among 1,149 multiple sclerosis patients reported an apparent survival advantage for 
people who were treated with beta interferon or glatiramer acetate (Tsai and Lee, 2013) but, due 
to the inclusion of ‘immortal time’ (Suissa, 2008) in the study design, the findings would be 
expected to be biased in favour of treatment, rendering the findings indeterminate. 
Interestingly, we found no evidence to suggest that later initiation of beta interferon (after age 40 
or five years of disease duration) was less advantageous than early initiation. While results from 
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some clinical trials have suggested a disadvantage with later (relative to earlier) Beta interferon 
initiation for other outcomes, including changes on magnetic resonance imaging, disability 
progression and transition from clinically isolated syndrome to definite multiple sclerosis (Bates, 
2011; Freedman, 2011), these observations are from highly select groups of patients, typically 
excluding older adults such as those over 50 or 55 years, or those with longer disease duration 
(IFNB Multiple Sclerosis Study Group, 1993; Jacobs et al., 1996; European Study Group on 
Interferon B-1b in Secondary Progressive MS, 1998; The OWIMS Study Group, 1999; 
Secondary Progressive Efficacy Clinical Trial of Recombinant Interferon-Beta-1a in MS Study 
Group, 2001).  In addition, findings from extension studies can potentially be affected by 
‘informative censoring’ if those who do not do well are more likely to drop out and be lost to 
follow-up (Sormani and Bruzzi, 2015). Our results suggest that delayed treatment with beta 
interferon can provide benefit, although we had limited power to assess the effects of early 
initiation due to a low number of ‘early initiators’. This limitation is not surprising given that it is 
less than two and half decades since the beta-interferons first became available, and multiple 
sclerosis is not shortly fatal; recent studies have shown people with multiple sclerosis, on 
average, survive into their eighth
 
decade of life (Kingwell et al., 2012; Scalfari et al., 2013; 
Leray et al., 2015; Lunde et al., 2017).  
Previously, we found no significant associations between disability progression, as measured by 
Expanded Disability Status Scale milestones, and beta interferon exposure, although evidence of 
such an association has been inconsistent between studies (Tramacere et al., 2015; Signori et al., 
2016). It is feasible that disability progression and survival are influenced by different factors 
and that an effect of beta interferon on survival is independent of any relationship with disability 
progression. Dissociation between outcomes in multiple sclerosis is not uncommon, notably for 
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relapses and Expanded Disability Status Scale score (Confavreux et al., 2000; Tremlett et al., 
2009). Further, death is unarguably a more definitive representation of survival, and less 
susceptible to measurement error than the Expanded Disability Status Scale is of disability. One 
plausible mechanism through which the beta interferons might influence mortality is by a 
reduction in the risk of viral infections (Goodbourn et al., 2000; Dhib-Jalbut and Marks, 2010). 
This study did not have sufficient power to assess death due to specific causes, such as 
infections; a larger cohort or longer follow-up would be required to gather sufficient cases by 
specific cause of death. Previous observations though have suggested a protective effect for 
hospitalizations for pneumonia/respiratory infection (Evans et al., 2014) and, with at least two 
years cumulative exposure to beta interferon, for bronchitis or upper respiratory infections (de 
Jong et al., 2017).  
We were able to assess the association between beta interferon and multiple sclerosis-related 
deaths, as defined by the causes listed on the death certificate. The majority (66%) of deaths 
were considered multiple sclerosis-related; this falls within the range reported from other 
multiple sclerosis cohorts (Koch-Henriksen et al., 1998; Bronnum-Hansen et al., 2004; Leray et 
al., 2007; Goodin et al., 2012a; Rodriguez-Antiguedad Zarranz et al., 2014), although some 
variation is to be expected due to different criteria for defining multiple sclerosis-related death 
and different ages and duration of follow-up. Similar to deaths due to any cause, we found a 
survival advantage for beta interferon exposure, with a 29% lower risk of multiple sclerosis-
related death among treated, compared to untreated, persons with relapsing-onset multiple 
sclerosis.  
The strengths of our study include up to 28 years follow-up of an international cohort with nearly 
6,000 relapsing-onset multiple sclerosis patients (more than 7000 in complementary analyses) 
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from two distinct regions in North America and Europe, all of whom were diagnosed by 
specialist multiple sclerosis-neurologists, and a sizable number of death outcomes (649, rising to 
956 in the complementary analyses). Access to population-based prospectively collected data 
ensured reliable and unbiased identification and coding of deaths, disease-modifying therapy 
exposure and, for the Canadian cohort, comorbidity information and estimates of socioeconomic 
status. The nested case-control approach with incidence density sampling provided an efficient 
study design with strict control of age, sex, year and disability level through matching, thus 
ensuring that controls were similar to cases and had the same duration of follow-up with equal 
opportunity for exposure to disease-modifying therapies during the same calendar time period. 
This approach has been shown to yield virtually identical findings to Cox regression modeling 
using the full cohort (Essebag et al., 2005). 
We were able to consider comorbidity and disability in our analyses; both were independent 
predictors of survival in our cohort and have previously been identified as important predictors 
of mortality in multiple sclerosis (Leray et al., 2007; Marrie et al., 2015; Salter et al., 2016). 
While the conservative approach for our main analysis focused on a cohort of persons with 
relapsing-onset multiple sclerosis who were naïve to disease-modifying therapy when the beta 
interferons were first approved, our complementary analyses, with study entry 10 years earlier 
and imputation of Expanded Disability Status Scale scores to include those with missing 
disability assessments, enabled inclusion of more cases; both provided similar findings of a 
survival advantage with beta interferon treatment. Because treatment status was unknown for 
some persons with relapsing-onset multiple sclerosis in the French cohort, they were censored at 
their last clinic visit. However, imputation of exposure to beta interferon treatment and re-
analysis after inclusion of their additional available follow-up time did not change the 
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interpretation of findings. Although the confidence intervals overlapped, the effect size was 
larger which suggests that any bias due to this missing data would likely have been towards an 
underestimate of the association. 
As with all observational studies, there is potential for residual confounding, despite our 
consideration of important predictors of mortality through matching or adjustment; information 
on smoking, or other health behaviours, for example were not captured. Indication bias cannot be 
completely ruled out; it is feasible that non-responders to treatment, or those with declining 
health, might have stopped treatment early and the results of the cumulative exposure analyses 
should therefore be interpreted cautiously. On the other hand, a survival advantage was observed 
even in the complementary analysis with exposure to disease-modifying therapy determined as 
any treatment at all (at least one day), akin to an ‘intention to treat’ approach. This ensured that 
responders and non-responders, and those who stopped treatment very early, were all considered 
treated. It has been suggested that an indication bias with beta interferon might be driven by a 
greater likelihood of treatment among persons with multiple sclerosis who are progressing or not 
doing well (Sormani and Bruzzi, 2015). If this were true it would tend to bias observed 
differences towards the null, implying that our estimates could be conservative. It is important to 
note that due to lower exposure rates to glatiramer acetate and the other multiple sclerosis 
therapies during the follow-up period there was insufficient power to assess their association 
with, or potential impact on, survival. These exposures were considered only as potential 
confounders of the relationship between beta interferon and survival and measures of their effect 
on survival cannot be interpreted from these analyses. 
Our study provides evidence for a significant survival advantage among people with relapsing-
onset multiple sclerosis who are exposed to beta interferons during routine clinical practice. 
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Further, a dose-response effect was observed with an increased survival associated with longer 
cumulative exposure to beta interferon. 
Worldwide, the beta interferons remain the most commonly used disease-modifying therapies to 
treat multiple sclerosis. These findings provide additional valuable information for patients and 
clinicians with respect to important and realistic treatment outcomes. Further work is warranted 
to assess whether this survival advantage extends to other disease-modifying therapies for 
multiple sclerosis and whether this observed survival advantage results in a measurable 
improvement in the quality of life lived.  
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FIGURE LEGEND 
Figure 1: Algorithm to classify multiple sclerosis-related death based on the 
underlying cause and multiple sclerosis as a contributing cause from the 
death certificate among people with multiple sclerosis 
All deaths with multiple sclerosis listed as the underlying cause were considered to be multiple 
sclerosis-related, as were deaths attributed (as the underlying cause) to suicide, certain diseases 
of the nervous system, sepsis, respiratory infection/inflammation or genitourinary system 
infection. Deaths due to certain other underlying causes; diseases of the circulatory system, 
malnutrition, dementia, other specific nervous system diseases, accidents and complications of 
medical care, were considered multiple sclerosis-related only if multiple sclerosis was mentioned 
as contributing to the death. Lastly, the remaining underlying causes, including cancer, were 
considered as not multiple sclerosis-related whether multiple sclerosis was mentioned as 
contributing or not.  
The cause of death data from the death certificate were accessed through the British Columbia 
Vital Statistics Agency in Canada and the ‘Répertoire National d’Identification des Personnes,’ 
and ‘Institut National de la Santé et de la Recherche Médicale’ in France. The underlying and 
contributing causes were coded by International Classification of Diseases version 9 and 10 
codes. The International Classification of Diseases-10 chapters were used to guide formulation 
and visualization of the algorithm.  
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Multiple 
sclerosis-related 
Not multiple 
sclerosis-related 
YES or NO YES or NO YES NO 
CAUSES OF DEATH THAT ARE 
LIKELY DUE TO MULTIPLE SCLEROSIS 
CAUSES OF DEATH THAT CAN 
BE DUE TO MULTIPLE SCLEROSIS 
CAUSES OF DEATH THAT ARE UNLIKELY 
DUE TO MULTIPLE SCLEROSIS 
Ch.1 Infectious and parasitic diseases 
 Sepsis 
 
Ch.6 Diseases of the nervous system  
 Multiple sclerosis and demyelinating 
diseases of the central nervous system 
 Paraplegia, tetraplegia and paralysis 
 Disorders of the hypoglossal nerve 
 Polyneuritis and polyneuropathy 
 Epilepsy 
 
Ch.10 Disease of the respiratory system 
 Pneumonia and influenza 
 Pneumonitis 
 
Ch.14 Diseases of the genitourinary 
system 
 Urinary tract or kidney infection 
 
Ch.19/20 External causes 
 Suicide 
 Accident due to asphyxiation  
Ch.4 Endocrine, nutritional and 
metabolic diseases  
 Malnutrition 
 
Ch.5 Mental and behavioural 
disorders 
 Dementia 
 
Ch.6 Diseases of the nervous system 
 Motor neuron disease 
 Alzheimer’s disease 
 Other degenerative diseases of  the 
nervous system 
 
Ch.9 Diseases of the circulatory 
system (all) 
 
Ch.19/20 External causes  
 Complications of surgery and care 
 Accidents (except due to 
asphyxiation) 
 Undetermined intent 
 
Ch.1 Infectious and parasitic diseases (all remaining)  
Ch.2 Cancer (all) 
Ch.3 Diseases of the blood/blood-forming organs (all) 
Ch.4 Endocrine, nutritional, and metabolic diseases (all 
remaining) 
Ch.5 Mental and behavioural disorders (all remaining)  
Ch.6 Diseases of the nervous system (all remaining) 
Ch.7 Diseases of the eye and adnexa (all) 
Ch.8 Diseases of the ear and mastoid process (all) 
Ch.10 Diseases of the respiratory system (all remaining) 
Ch.11 Diseases of the digestive system (all) 
Ch.12 Diseases of the skin and subcutaneous tissue (all) 
Ch.13 Diseases of the musculoskeletal system and 
connective tissue (all) 
Ch.14 Diseases of the genitourinary system (all 
remaining) 
Ch.15 Pregnancy, childbirth and the puerperium (all) 
Ch.16 Conditions originating in the perinatal period (all) 
Ch.17 Congenital malformations, deformations,  and 
chromosomal abnormalities (all)  
Ch.18 Not elsewhere classified and unknown (all) 
Ch.19/20 External causes (all remaining) 
Multiple sclerosis listed 
as contributing cause 
Multiple sclerosis listed 
as contributing cause 
Multiple sclerosis listed 
as contributing cause 
Table 1: Characteristics of the all-cause death cases and their matched controls 
from the combined Canadian and French Multiple Sclerosis cohorts 
 
a
CASES 
(n=649) 
b
CONTROLS 
(n=8,412)
 
c
P value
 
d
Age in years; mean (SD) 50.7 (11.4) 50.3 (10.6) 0.002 
Sex; n (%)                                             Men 
Women 
195 (30.0) 
454 (70.0) 
195 (30.0) 
454 (70.0) 
 
n/a 
Country; n (%) 
Canada (British Columbia)                          
France (Rennes) 
 
569 (87.7) 
80 (12.3) 
 
569 (87.7) 
80 (12.3) 
 
 
n/a 
Expanded Disability Status Scale; n (%) 
< 3.0 
 3.5 - 5.0 
5.5 - 6.5 
7 - 9.5 
 
160 (24.7) 
131 (20.2) 
164 (25.3) 
194 (29.9) 
 
160 (24.7) 
131 (20.2) 
164 (25.3) 
194 (29.9) 
 
 
 
n/a 
e
Socioeconomic status; n (%) 
   Lowest                 
Mid-Low 
Middle 
Mid-High 
Highest 
 
108 (19.0) 
93 (16.3) 
105 (18.5) 
132 (23.2) 
107 (18.8) 
 
99.2 (17.4) 
94.1 (16.5) 
114.7 (20.2) 
126.9 (22.3) 
117.7 (20.7) 
 
 
 
 
 
0.20 
d
Disease duration (years);  mean (SD) 17.1 (11.4) 17.5 (7.9) 0.42 
f
Comorbidity Index; mean (SD) 
       
 0.24 (0.65) 0.18 (0.25) 0.02 
g
Follow-up time (years); mean (SD) 9.3 (4.6) 9.3 (4.6) n/a 
h
Disease modifying therapies; n (%)                                           
Beta interferon 
 
85 (13.1) 
 
113.3 (17.4) 
 
0.004 
Glatiramer acetate 24 (3.7) 24.1 (3.7) 0.77 
Other disease-modifying therapiess 45 (6.9) 42.0 (6.5) 0.36 
 
Cumulative dose beta interferon; n (%)                 
Lower (six months - three years) 
 Higher (more than three years) 
 
 
53 (8.2) 
32 (4.9) 
 
 
49.4 (7.6)   
63.8 (9.8) 
 
 
  
 <0.001 
 
Early / Late Start beta interferon; n (%) 
Time since onset        
Early (less than five years) 
                       Late (at least five years) 
 
 
 
31 (4.8) 
54 (8.3) 
 
 
 
29.9 (4.6) 
83.4 (12.8) 
 
 
 
 
0.003 
Age                                     
Early (under 40 years) 
Late (40 years or over) 
 
24 (3.7) 
61 (9.4) 
 
28.0 (4.3) 
85.3 (13.1) 
 
 
0.01 
a
649 of 742 deaths were successfully matched to at least one control. After matching 100% of the deaths by sex, six 
cases did not have a match for age or Expanded Disability Status Scale. For the remaining 87 unmatched cases, there 
was no available control with a matching calendar year. 
b
To account for variation in the number of controls per case 
(1-20) between risk sets, all means, SDs, n and % presented here were weighted by the inverse of the number of 
controls in each set. 
c
Univariate conditional logistic regression 
d
Measured at study entry. 
e
Socioeconomic status 
(neighbourhood income quintile measured at study entry (for the 569 Canadian cases and their controls only); 4% of 
the cases and 3% of their controls had an unknown SES (missing) at study entry 
f
Charlson Comorbidity Index 
measured during the 12 months before study entry (for the 569 Canadian cases and their controls only); potential 
scores range from zero to 9.0 and a higher score indicates greater comorbidity burden 
g
Follow-up time from study 
entry date to death in the cases and equivalent time point for the controls. 
h
Disease-modifying therapy exposure 
during follow-up; beta interferon and glatiramer acetate exposure defined as at least six months; Other disease-
modifying therapy exposure defined as any exposure. 
Key: SD: Standard deviation. n/a: not applicable (as cases and controls were matched as per the study design).  
Table 2: Estimates of association between beta interferon exposure and all-cause death for 
the Canadian and French multiple sclerosis cohorts separately and combined. 
a
OR (95% CI)   CANADA 
f
Cases: 569
 
FRANCE 
f
Cases: 80
 
COMBINED 
f
Cases: 649
 
             
b
Beta interferon 0.67 (0.50 - 0.90) 0.67 (0.35 - 1.28) 0.68 (0.53 - 0.89) 
b
Glatiramer acetate 
c
Other disease-modifying therapy 
d
Age in years 
e
Comorbidity burden 
1.26 (0.73 - 2.16) 
1.26 (0.69 - 2.28) 
1.04 (1.01 – 1.07) 
1.18 (1.02 – 1.36) 
0.78 (0.32 - 1.92) 
1.37 (0.76 - 2.46) 
1.04 (0.95 – 1.15) 
1.11 (0.70 - 1.78) 
1.27 (0.84 – 1.92) 
1.04 (1.01 – 1.07) 
 
 
b
Cumulative days of beta interferon 
Lower (six months to three years) 
 Higher (more than three years) 
 
 
0.95 (0.67 - 1.36)  
0.46 (0.30 - 0.70) 
 
 
1.11 (0.52 - 2.40) 
0.37 (0.15 - 0.95) 
 
 
1.00 (0.73 - 1.38) 
0.44 (0.30 - 0.66) 
 
b
Early / Late Start beta interferon 
Time since onset 
Early (less than five years) 
 Late (five or more years) 
 
 
 
1.16 (0.73 – 1.85) 
0.54 (0.38 - 0.76) 
 
 
 
0.34 (0.10 - 1.19) 
0.84 (0.42 - 1.69) 
 
 
 
0.93 (0.61 - 1.43) 
0.61 (0.45 - 0.83) 
Age               
Early (under 40 years) 
 Late (40 years or older) 
 
0.89 (0.49 - 1.59) 
0.63 (0.46 - 0.87) 
 
0.58 (0.19 - 1.77) 
0.72 (0.34 - 1.53) 
 
0.83 (0.49 - 1.40) 
0.65 (0.48 - 0.87) 
a
All ORs are adjusted. Model covariates: beta interferon exposure, glatiramer acetate exposure, other disease-
modifying therapy exposure, age at study entry and, for Canada only, comorbidity burden calculated for the year 
before study entry. 
b
Reference category is less than six months exposure.
 c
Reference category is no exposure. 
d
Age 
in years (continuous). 
e
Charlson Comorbidity Index. 
f
There were between 1 and 20 matched controls for each case. 
Key: OR = Odds ratio; CI = Confidence interval; bold indicates p<0.05.    
Table 3: Estimates of association between beta interferon exposure and all-cause deaths for 
the combined Canadian and French multiple sclerosis cohorts by sex 
a
OR (95% CI)   WOMEN 
e
Cases: 454
 
MEN 
e
Cases: 195
 
             
b
Beta interferon 
b
Glatiramer acetate 
c
Other disease-modifying therapy 
d
Age 
0.78 (0.58 - 1.06) 
1.19 (0.71 - 2.02) 
1.68 (1.06 - 2.67) 
1.05 (1.01 – 1.08) 
0.42 (0.24 - 0.77) 
0.89 (0.31 - 2.53) 
0.54 (0.21 – 1.42) 
1.03 (0.98 – 1.09) 
 
b
Cumulative exposure beta interferon 
Lower (six months to three years) 
Higher (more than three years) 
 
 
1.25 (0.86 - 1.81)   
0.49 (0.32 - 0.76) 
 
 
0.55 (0.28 - 1.08) 
0.29 (0.12 - 0.70) 
 
b
Early / Late Start beta interferon 
Time since onset 
Early (less than five years) 
 Late (five or more years) 
 
 
 
1.08 (0.68 - 1.73) 
0.68 (0.47 - 0.97) 
 
 
 
0.47 (0.16 - 1.36) 
0.42 (0.22 - 0.78) 
Age               
Early (under 40 years) 
 Late (40 years or older) 
 
0.99 (0.55 - 1.80) 
0.74 (0.53 - 1.03) 
 
0.49 (0.16 - 1.44) 
0.41 (0.20 - 0.80) 
a
Model covariates: beta interferon exposure, glatirmarer acetate exposure, other disease-modifying therapy 
exposure, age at study entry in years. 
b
Reference category = Less than six months exposure.
 c
Reference category = 
No exposure. 
d
Age in years (continuous). 
e
There were between 1 and 20 matched controls for each case. 
OR = Odds ratio; CI = Confidence interval; bold indicates statistically significant estimates (p<0.05). 
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Supplementary Methods 1: Description and sources of the clinical and 
administrative health data 
 
The cohort included all adults with relapsing-onset multiple sclerosis initially registered at one of the 
four multiple sclerosis clinics in British Columbia (1980-2004) or the Rennes multiple sclerosis clinic 
(1976-2013), and diagnosed by a multiple sclerosis-specialist neurologist by Poser or McDonald 
criteria (Poser et al., 1983; McDonald et al., 2001). The multiple sclerosis clinical databases in British 
Columbia and Rennes (Leray et al., 2007; Tremlett et al., 2010), provided the following information: 
sex, birthdate, symptom onset date, disease course,  Expanded Disability Status Scale scores, and 
initiation/cessation dates of the disease-modifying therapies for multiple sclerosis including 
immunosuppressants. Dates and causes of death were accessed from the British Columbia Vital 
Statistics Agency (BC Vital Statistics Agency, 2015), the French ‘Répertoire National d’Identification 
des Personnes,’ and the ‘Institut National de la Santé et de la Recherche Médicale’. British Columbia 
drug prescription data was provided by PharmaNet (British Columbia Ministry of Health, 2015a); this 
data extract captured all dispensations of disease modifying drugs at community and outpatient 
pharmacies in British Columbia and complemented the drug exposure data from the British Columbia 
Multiple Sclerosis database. The Medical Service Plan (British Columbia Ministry of Health, 2015b) 
provided dates and International Classification of Diseases System diagnostic codes for physician 
visits, and the Discharge Abstracts (British Columbia Ministry of Health, 2015c) data provided dates 
and diagnostic codes for all hospital admissions. Registration dates in the provincial health care plan 
and quintiles of neighbourhood level socioeconomic status were accessed from the British Columbia 
Registration and Premium Billing files (British Columbia Ministry of Health, 2015d). The time periods 
of data availability and sources of the administrative data are shown in Supplementary Table 1. 
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Supplementary Methods 2: Complementary analyses methods and results 
Complementary analyses were conducted to facilitate inclusion of additional data, follow-up time or 
patients, and to test assumptions: 
1. Allowing an earlier study entry (1
st
 January 1986) 
2. Imputing Expanded Disability Status Scale scores for those without a score at study entry 
3. ‘Exposure’ to beta interferon or glatiramer acetate classified as any exposure of at least one day 
(akin to an ‘Intention to Treat’ approach). 
4. Imputation of unknown beta interferon exposure status for the French cohort  
Details of these methods and the results of these analyses are outlined below. 
1. Earlier Study Entry Date (1986) 
Methods 
To include the potential multiple sclerosis cases and controls with disease-modifying therapy or 
immunosuppressant exposure prior to 1996, the earliest study entry date was set at 1
st
 January 1986. 
All methods used to select cases and controls remained the same. Also, the same analytical approach 
was used as for the main analysis, but without adjustment for comorbidity in British Columbia, Canada 
because some of the required information, i.e. diagnostic codes generated from physician encounters, 
was not available pre-1991. This complementary approach enabled: (i) inclusion of those patients who 
were exposed to disease-modifying therapies, including beta interferon or immunosuppressants, before 
approval of beta interferon in Canada and France and who were therefore excluded from the main 
analyses; and (ii) a longer potential follow-up time (up to 28 years; from 1986 to 2013). Individuals 
with no available Expanded Disability Status Scale score within three years of their study entry date 
were excluded. 
Results 
There were 1,096 deaths in the multiple sclerosis cohort between 1986 and the end of 2013 and the 
mean age at death was 61 (SD 13) years. Of these, 892 were successfully matched to up to 20 controls. 
In comparison to the main analysis, the earlier study entry date allowed inclusion of a larger number of 
cases from the Canadian cohort (820) and slightly less from the French cohort (72), due to missing 
Expanded Disability Status Scale scores in the earlier years. The cases and controls were younger than 
those in the main analysis (mean age 41 years; SD 9) and had a shorter multiple sclerosis disease 
duration (mean of 10 years; SD 9) at study entry, as expected due to the potentially earlier study entry 
date. After adjustment for age and exposure to glatiramer acetate or other disease-modifying therapies, 
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persons who were exposed to beta interferon had a higher odds of survival compared to persons who 
were not exposed (OR:0.62; 95% CI 0.49-0.80); i.e. findings were consistent with those from the main 
analysis. The results are shown in Supplementary Table 3.  
2. Imputation of missing Expanded Disability Status Scale scores 
Methods 
The main analysis (with 1
st
 January 1996 as the study entry) was repeated with inclusion of all 
individuals regardless of whether their Expanded Disability Status Scale score was available; for 
individuals without a score at study entry, the score was imputed 10 times based on age, sex, multiple 
sclerosis disease duration and country with the proportional odds model. 
The methods used for the main analyses were repeated but with matching of controls to cases by sex, 
age (+/- five years), calendar year and country, and not by category of Expanded Disability Status 
Scale. The conditional logistic regression models were adjusted for EDSS (as a continuous measure), 
age, glatiramer acetate exposure and other disease-modifying therapy exposure, and for comorbidity in 
Canada.  
Results 
After inclusion of individuals with missing Expanded Disability Status Scale score at study entry, the 
combined Canadian and French cohort included 7,009 persons with relapsing-onset multiple sclerosis 
who were naïve to disease-modifying therapy at study entry; 75% were women and the mean age was 
42 (SD 12) years.  There were 989 all cause deaths and 956 of these cases were successfully matched 
to up to 20 controls by sex, age and calendar year at entry. The cases and controls had an average age 
of 50 years (SD 9) at entry (similar to the average age of the cases and controls included in the main 
analysis). After adjustment for Expanded Disability Status Scale score, age and exposure to glatiramer 
acetate or other disease-modifying therapies, similar estimates to the main analysis were obtained. 
Persons with relapsing-onset multiple sclerosis who were exposed to beta interferon had a higher odds 
of survival compared to those who were not exposed; the results from the 10 imputations were very 
similar (OR:0.62; 95% CI 0.49-0.78). The full model results are shown in Supplementary Table 4. 
3. ‘Intention to Treat’ 
Methods 
The main analysis (with 1
st
 January1996 as the study entry) was repeated with exposure to beta 
interferon, and to glatiramer acetate, defined as at least one day. This ‘Intention to Treat’ analysis 
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ensured that responders and non-responders, and those that stopped treatment very early, were all 
considered treated. 
Results  
The same 649 cases and their matched controls from the main analysis were included. Persons with 
relapsing-onset multiple sclerosis who were exposed to beta interferon had a higher odds of survival 
compared to those who were not exposed (OR:0.76; 95% CI:0.59-0.97); estimates were similar to 
those derived from the main analysis. The results are shown in Supplementary Table 5. 
4. Imputation of unknown beta interferon exposure status in the French cohort 
Methods 
The main analysis (with 1
st
 January 1996 as the study entry) was repeated for the French cohort. For 
those with unknown beta interferon treatment status after their last clinic visit (i.e. less than 180 days 
exposure to this date), the number of days of beta interferon exposure were imputed over the period 
between the last multiple sclerosis clinic visit and study end, based on age, sex, Expanded Disability 
Status Scale score and disease duration with the Markov Chain Monte Carlo method; this was repeated 
10 times. As death/survival information was available for all persons with multiple sclerosis, this 
allowed inclusion of all follow-up time for the French cohort. As for the main analyses, controls were 
matched to cases by sex, age (+/- five years), calendar year and Expanded Disability Status Scale 
score. The conditional logistic regression model was adjusted for age only; with a second model 
adjusted for age, glatiramer acetate and other disease-modifying therapy exposure (exposure status to 
glatiramer acetate and other disease-modifying therapies were based on the status recorded at the last 
clinic visit, with no change assumed through to the study end).  
Results  
The treatment status after the last clinic visit was unknown for 528 patients in the French cohort. With 
imputation of treatment status and inclusion of the follow-up time after the last clinic visit for these 
individuals, 95 all cause deaths were successfully matched with up to 20 controls. After adjustment for 
age, and then for age, glatiramer acetate or other disease-modifying therapy exposure, the estimates of 
the effect of beta interferon were comparable, or even greater, than those seen in the main analysis 
(although all CIs overlapped).  Persons with multiple sclerosis who were exposed to beta interferon 
had a lower risk of death compared to those who were not exposed; the results from the 10 repeated 
imputations were very similar (OR:0.23; 95% CI 0.13-0.41). The full model results are shown in 
Supplementary Table 6.  
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Supplementary Tables 
 
Supplementary Table 1: Data sources and years of availability in British Columbia, Canada and 
Rennes, France 
 
 British Columbia, 
Canada 
Rennes, 
France 
 Description of source cohorts 
 Adults (>18 years), relapsing-onset 
multiple sclerosis, registered at a 
British Columbia multiple sclerosis 
clinic 1980 - 2004 
Adults (> 18 years),relapsing-onset 
multiple sclerosis, registered at the 
Rennes multiple sclerosis clinic 
1976 - 2013 
Data elements Databases accessed and dates of data availability 
Sex; birth date; onset date; disease 
course; Expanded Disability Status 
Scale scores; beta interferon, 
glatiramer acetate and all other 
disease-modifying therapy start/stop 
dates 
British Columbia Multiple Sclerosis 
Database 
1980 - 2008 
 
Rennes Multiple Sclerosis Database 
1976 - 2013 
Death date; all causes listed on the 
death certificate 
 
British Columbia Vital Statistics 
Deaths  
1986 – 2013 
Répertoire National d’Identification 
des Personnes,’ 
and 
the ‘Institut National de la Santé et de 
la Recherche Médicale’ January  
1986 - 2013 
Prescriptions filled (dispensed), 
including disease-modifying 
therapies 
British Columbia PharmaNet 
1996 – 2013 
N/A 
Physician visit dates; International 
Classification of Diseases codes 
British Columbia Medical Services 
Plan, 
1991 – 2013 
N/A 
Hospital admission and discharge 
dates; International Classification of 
Diseases codes 
British Columbia Discharge Abstract 
Database 
1986 – 2013 
N/A 
Registration/ cancellation dates in the 
British Columbia health care 
program; socioeconomic status 
British Columbia Registration and 
Premium Billing files, 
1986 – 2013 
N/A 
N/A = not applicable
7 
 
Supplementary Table 2: Number of controls per case for the 649 cases included in the 
main analysis of beta-interferon treatment for multiple sclerosis and mortality 
 
Number of controls per case Number of cases (of 649 in total) 
1 54 
2 43 
3 28 
4 24 
5 31 
6 16 
7 11 
8 17 
9 19 
10 16 
11 15 
12 12 
13 12 
14 8 
15 7 
16 13 
17 10 
18 8 
19 7 
20 298 
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Supplementary Table 3: Estimates of association between all-cause deaths and 
disease modifying drug exposure for the Canadian and French multiple sclerosis 
cohorts separately and combined with earliest study entry date of 1
st
 January 1986 
 
a
OR (95% CI)  CANADA 
e
Cases: 820
 
FRANCE 
e
Cases: 72
 
COMBINED 
e
Cases: 892
 
             
b
Beta interferon 0.60 (0.46 - 0.78) 0.87 (0.42 - 1.79) 0.62 (0.49 – 0.80) 
b
Glatiramer acetate 1.17 (0.70 – 1.95) 0.71 (0.25 – 2.03) 1.06 (0.67 – 1.69) 
c
Other disease-modifying therapy
 
d
Age
 
1.50 (0.96 - 2.36) 
1.04 (1.02 – 1.07) 
1.71 (0.87 – 3.38) 
1.08 (0.97 – 1.21) 
1.52 (1.05 – 2.20) 
1.05 (1.02 – 1.07) 
 
b
Cumulative exposure beta interferon 
Lower (six months to three years) 
 Higher (more than three years) 
 
0.80 (0.58 – 1.12) 
0.43 (0.29 – 0.63) 
 
1.81 (0.76 – 4.27) 
0.33 (0.10 – 1.02) 
 
0.90 (0.66 – 1.22) 
0.41 (0.29 – 0.59) 
 
b
Early / Late Start beta interferon 
Time since onset 
Early (less than five years) 
                       Late (at least5 years) 
 
 
1.09 (0.68 – 1.76) 
0.50 (0.37 – 0.68) 
 
 
0.42 (0.11 – 1.52) 
1.18 (0.53 – 2.64) 
 
 
0.91 (0.58 – 1.42) 
0.56 (0.42 – 0.74) 
Age              
Early (under 40 years) 
 Late (40 years or older)) 
 
0.88 (0.49 – 1.58) 
0.55 (0.41 – 0.74) 
 
0.60 (0.20 – 1.79) 
1.13 (0.46 – 2.78) 
 
0.79 (0.48 – 1.33) 
0.59 (0.45 – 0.77) 
a
Model covariates: beta interferon exposure, glatiramer acetate exposure, other disease-modifying therapy 
exposure and age at study entry.  
b
Reference category = Less than six months exposure. 
 c
Reference category = No 
exposure. 
d
Age in years (continuous).  
e
There were between one and 20 matched controls for each case. 
OR = Odds ratio; CI = Confidence interval; bold indicates statistically significant estimates (p<0.05).  
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Supplementary Table 4:   Estimates of association between all-cause deaths and disease 
modifying drug exposure for the Canadian and French multiple sclerosis cohorts 
separately and combined with imputed Expanded Disability Status Scale scores 
 
a
OR (95% CI)  CANADA 
g
Cases: 834
 
FRANCE 
g
Cases: 122
 
COMBINED 
g
Cases: 956
 
             
b
Beta interferon 0.63 (0.49 – 0.81) 0.61 (0.36 – 1.05) 0.62 (0.49 - 0.78) 
b
Glatiramer acetate 1.22 (0.76 – 1.96) 1.22 (0.61 – 2.41) 1.22  (0.81 - 1.59) 
c
Other disease-modifying therapy
 
d
Expanded Disability Status Scale 
e
Age 
f
Comorbidity burden
 
1.02 (0.58 – 1.79) 
1.30 (1.26 – 1.34) 
1.06 (1.03 – 1.08) 
1.20 (1.08 – 1.34) 
1.15 (0.73 – 1.79) 
1.49 (1.35 – 1.65) 
1.03 (0.96 – 1.11) 
1.14  (0.83 – 1.79) 
1.32 (1.28 – 1.36) 
1.06 (1.03 – 1.08) 
 
 
b
Cumulative exposure beta interferon 
Lower (six months to three years) 
 Higher (more than three years) 
 
 
0.86 (0.63 – 1.18) 
0.44 (0.30 – 0.65) 
 
 
1.04 (0.55 – 1.97) 
0.30 (0.13 – 0.73) 
 
 
0.89 (0.67 – 1.17) 
0.40 (0.28 – 0.57) 
    
b
Early / Late Start beta interferon 
Time since onset 
Early (less than five years) 
                       Late (at least5 years) 
 
 
1.21 (0.81 – 1.81) 
0.49 (0.36 – 0.67) 
 
 
0.28 (0.09 – 0.84) 
0.78 (0.44 – 1.38) 
 
 
0.87 (0.60 – 1.28) 
0.54 (0.41 – 0.71) 
Age               
Early (under 40 years) 
 Late (40 years or older) 
 
0.86 (0.52 – 1.44) 
0.58 (0.43 – 0.77) 
 
0.45 (0.19 – 1.09) 
0.72 (0.39 – 1.35) 
 
0.72 (0.46 – 1.11) 
0.59 (0.46 – 0.77) 
a
Model covariates: beta interferon exposure, glatiramer acetate exposure, other disease-modifying therapy 
exposure, EDSS at study entry, age at study entry and, for Canada only, comorbidity burden calculated for the year 
before study entry.  
b
Reference category = Less than six months exposure. 
c
Reference category = No exposure. 
d
 
Expanded Disability Status Scale as a continuous measure. 
e
Age in years (continuous). 
f
Charlson Comorbidity 
Index 
g
There were between one and 20 matched controls for each case. 
OR = Odds ratio; CI = Confidence interval. Bold indicates statistically significant estimates (p<0.05). 
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Supplementary Table 5: Estimates of association between all-cause deaths and 
disease modifying drug exposure for the Canadian and French multiple 
sclerosis cohorts separately and combined using the ‘Intention to Treat’ 
approach 
a
OR (95% CI)  CANADA 
e
Cases: 569
 
FRANCE 
e
Cases: 80
 
COMBINED 
e
Cases: 649
 
          
b
Beta interferon
 
b
Glatiramer acetate  
b
Other disease-modifying therapy 
c
Age 
d
Comorbidity burden 
 0.73 (0.55-0.96) 
1.46 (0.92-2.33) 
1.24 (0.68-2.26) 
1.04 (1.01-1.08) 
1.17 (1.02-1.35) 
0.81 (0.43-1.53) 
0.75 (0.32-1.75) 
1.39 (0.77-2.50) 
1.04 (0.95-1.15) 
 
0.76 (0.59-0.97) 
1.24 (0.82-1.88) 
1.26 (0.84-1.90) 
1.04 (1.01-1.07) 
a
Model covariates: IFNB exposure (at least one day), glatiramer acetate exposure (at least one day), other disease-
modifying therapy exposure (at least one day), age at study entry in years and for Canada only, comorbidity 
burden calculated for the year before study entry. 
b
Reference category = No disease-modifying therapy exposure. 
c
Age in years (continuous). 
d
Charlson Comorbidity Index. 
e
There were between one and 20 matched controls for 
each case. 
OR = Odds ratio; CI = Confidence interval. Bold indicates statistically significant estimates (p<0.05). 
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Supplementary Table 6:  Estimate of association between all-cause deaths and disease 
modifying drug exposure for the French multiple sclerosis cohort with imputation of 
unknown beta interferon exposure 
a
OR (95%CI)  
5
Cases: 95
 
c
Beta interferon 
d
Age 
0.23 (0.13-0.41) 
1.07 (0.98-1.59) 
 
b
OR (95%CI) 
 
          
c
Beta interferon
 
c
Glatiramer acetate  
c
Other disease-modifying therapy 
d
Age 
0.23 (0.13-0.41) 
0.98 (0.40-2.39) 
1.41 (0.84-2.39) 
1.07 (0.98-1.17) 
a 
Model covariates: beta interferon exposure (at least 180 days) and age at study entry in years. 
b
Model covariates: 
beta interferon exposure (at least 180 days), age at study entry in years, glatiramer acetate exposure at least 180 
day), and other disease-modifying therapy exposure (at least one day). 
c
Reference category = No disease-
modifying therapy exposure. 
d
Age in years (continuous). 
e
There were between one and 20 matched controls for 
each case. 
OR = Odds ratio; CI = Confidence interval. Bold indicates statistically significant estimates (p<0.05). 
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